3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
3
Other hematologic neoplasm
1
Dermatologic
1
Conditions
Ureteral Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Peripheral Blood Stem Cell Transplantation
42
fludarabine phosphate
37
Cyclophosphamide
36
Mycophenolic Acid
28
Whole-Body Irradiation
26
Cyclosporine
25
Busulfan
25
Tacrolimus
22
Antilymphocyte Serum
21
Methotrexate
16
Filgrastim
16
Etoposide
15
Methylprednisolone
13
Melphalan
13
Radiotherapy
12
Flow Cytometry
11
Psychiatric Rehabilitation
10
Therapeutics
9
Rituximab
9
Polymerase Chain Reaction
8
Bortezomib
8
Gemcitabine
7
Cord Blood Stem Cell Transplantation
7
sargramostim
6
Vorinostat
6
Sirolimus
6
tanespimycin
5
Transplantation
5
Thiotepa
5
Carboplatin
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma, Follicular
×
abexinostat
×
Dermatologic
×
Clear all
NCT00724984
2014-04-07
PCYC-0403
Pharmacyclics LLC.
Phase 1/2
Completed
55 enrolled
11 charts